This study is testing a local anesthetic (numbing medicine) to suppress pain. Bupivacaine and lidocaine are FDA approved local anesthetics that may decrease pain following surgery. Patients will receive either 2% lidocaine, 0.5% bupivacaine, or placebo with epinephrine 1:200,000 as a numbing medicine at the end of root canal surgery. Small pieces of gum will be taken before and after surgery and 2 days later to analyze chemicals that may be related to pain sensation.
We hypothesize that the use of the LLA bupivacaine will promote local inflammation leading to increased pain and central sensitization as evaluated by increase in pain at later time points. Hence our main hypothesis to be evaluated and statistically tested for our primary endpoint (Aim 1) is: HO: There is no difference in mean levels of biochemical mediators of inflammation between groups. HA: The bupivacaine group has higher levels of biochemical mediators following surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Enrollment
11
Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
University of Maryland, Baltimore College of Dental Surgery
Baltimore, Maryland, United States
Assess the local inflammatory response as measured by tissue expression of the prostanoid enzymes cyclooxygenase (COX-2) and other cytokines and inflammatory mediators.
The difference in inflammatory gene expression between treatment groups.
Time frame: 48 hours
Evaluate the clinical outcome of postoperative pain following endodontic surgery, as measured by pain category and visual analog scale (VAS) and postoperative analgesic requirements.
The subject-reported pain measured at 48 hours after surgery.
Time frame: 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.